Effect of low dose acetylsalicylic acid and anticoagulant on clinical outcomes in COVID‐19, analytical cross‐sectional study. Issue 4 (11th July 2022)

• Record Type: Journal Article
• Authors: Malik, Muhammad B.; Amer, Samar A.; Merrell, Eric; Russo, Ronald; Riley, Jeffrey B.; Scro, Austin; James, Elizabeth; Anuforo, Anderson; Adhikari, Soumya; Siciliano, Rosalie; Chebaya, Philip; Darling, Edward; Kuhn, Michael; Nieman, Gary; Shawkat, Ahmed; Aiash, Hani
• Is Part Of: Health science reports. Volume 5:Issue 4(2022)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2022-07-11
• Subjects: acetylsalicylic acid -- anticoagulation -- ASA -- COVID‐19 -- preventative medicine; 610
• DOI: 10.1002/hsr2.699
• Languages: English
• ISSNs: 2398-8835

Abstract

Abstract: Background and aims: The therapeutic strategy for the treatment of known sequelae of COVID‐19 has shifted from reactive to preventative. In this study, we aim to evaluate the effects of acetylsalicylic acid (ASA), and anticoagulants on COVID‐19 related morbidity and mortality. Methods: This record‐based analytical cross‐sectional study targeted 539 COVID‐19 patients in a single United States medical center between March and December 2020. Through a random stratified sample, we recruited outpatient ( n = 206) and inpatient ( n = 333) cases from three management protocols, including standard care (SC) ( n = 399), low‐dose ASA only (ASA) ( n = 112), and anticoagulation only (AC) ( n = 28). Collected data included demographics, comorbidities, and clinical outcomes. The primary outcome measure was inpatient admission. Exploratory secondary outcome measures included length of stay, 30‐day readmission rates, medical intensive care unit (MICU) admission, need for mechanical ventilation, the occurrence of acute respiratory distress syndrome (ARDS), bleeding events, clotting events, and mortality. The collected data were coded and analyzed using standard tests. Results: Age, mean number of comorbidities, and all individual comorbidities except for asthma, and malignancy were significantly lower in the SC compared to ASA and AC. After adjusting for age and comorbidity via binary logistic regression models, no statistical differences were found between groups for the studied outcomes. When compared to the SC group, ASA had lower 30‐day readmission rates (odds ration [OR] 0.81 95% confidence interval [CI] 0.35–1.88, p = 0.63), MICU admission (OR 0.63 95% CI 0.34–1.17, p = 0.32), ARDS (OR 0.71 95% CI 0.33–1.52, p = 0.38), and death (OR 0.85 95% CI 0.36–1.99, p = 0.71). Conclusion: Low‐dose ASA has a nonsignificant but potentially protective role in reducing the risk of COVID‐19 related morbidity and mortality. Our data suggests a trend toward reduced 30‐day readmission rates, ARDS, MICU admissions, need for mechanical ventilation, and mortality compared to the standard management protocol. Further randomized control trials are needed to establish causal effects.